Drugs / tetanus toxoid
tetanus toxoid
also known as
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed · Tdap · Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine · 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) · DT-pediatric · DTaP · Equilis te · PCV24 · +15 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Hexacima | — | 2013-02-22 | europa.eu ↗ |
| Approved | EU (EMA) | Tritanrix HepB | — | 1996-07-19 | europa.eu ↗ |
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01933776 | Aug → Nov 2013 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00707148 | Jan 2009 → May 2012 | diphtheria, pertussis, tetanus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00639639 | Feb 2006 → Apr 2017 | malignant glioma | Gary Archer Ph.D. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07600983 | May → Nov 2026 expected | pneumococcal infection | CanSino Biologics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06939777 | Apr → Dec 2025 | tetanus | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05183516 | May → Dec 2023 | Alzheimer disease | Mindful Diagnostics and Therapeutics, LLC | Unknown | No outcome recorded |
| Phase 1/2 | NCT05480800 | Sep 2022 → Sep 2024 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT02587520 | Oct 2015 → Feb 2017 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00027833 | Dec 2001 → ? | colorectal cancer | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04490018 | Mar 2021 → May 2022 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT00287677 | Jan 2006 → Jul 2009 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00777257 | Apr 2005 → Mar 2007 | diphtheria, meningitis, meningococcemia, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00004735 | Feb 2000 → Sep 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT00369291 Background | Sep 2003 → May 2010 | germ cell tumor, leukemia, plasma cell neoplasm | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06302374 Background | Mar → Nov 2023 | tetanus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01187433 Comparator | Aug 2010 → Oct 2012 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT02628886 Background | Mar 2016 → Feb 2019 | pneumonia | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03606096 Comparator | Jan 2019 → May 2022 | pertussis | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT02570347 Background | May 2016 → Oct 2019 | snakebite envenomation | Jawaharlal Institute of Postgraduate Medical Education & Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01629589 Comparator | Jun 2012 → Mar 2013 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-10 | GlaxoSmithKline | Regulatory US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants gsk.com ↗
We’re immensely proud to have the first-ever Tdap vaccine approved by the FDA specifically for this use during pregnancy. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-25 | CanSino Biologics Inc. | CanSinoBIO Advances Pneumococcal Disease Prevention Strategy with Initiation of Phase I/II Trial for PCV24 cansinotech.com ↗ |
| 2026-01-05 | CanSino Biologics Inc. | CanSinoBIO Advances Pneumococcal Vaccine Portfolio as PCV24 Receives Clinical Trial Approval cansinotech.com ↗ |
| 2022-10-10 | GlaxoSmithKline | US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants gsk.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tetanus toxoid | “mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis” NCT03606096 ↗9“Vaccination (Hepatitis A+B + tetanus toxoid) at week 16” NCT00287677 ↗ |
| Known as | 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07600983 ↗ |
| Known as | DT-pediatric | “tetanus toxoid immunizations (known as DTaP, DT-pediatric, or Td)” NCT00004735 ↗ |
| Known as | DTaP | “tetanus toxoid immunizations (known as DTaP, DT-pediatric, or Td)” NCT00004735 ↗ |
| Known as | Equilis te | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | PCV24 | “24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)” NCT07600983 ↗ |
| Known as | PCV24 vaccine | “1 dose ( 0.5ml) of PCV24 vaccine (dose M)” NCT07600983 ↗ |
| Known as | Tdap | “Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) immunization of women in the third trimester of pregnancy represents an opportunity to...” NCT00707148 ↗2“Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine)” NCT00777257 ↗ “Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular” NCT00777257 ↗ |
| Known as | Tetanus toxoid component of hexacima | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of hexavac | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of hexyon | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of infanrix hepb | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of infanrix hexa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of infanrix penta | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of primavax | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of quintanrix | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of triacelluvax | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of tritanrix hepb | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid component of vaxelis | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108875 ↗ |
| Known as | Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480800 ↗ |
| Known as | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed | “Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine)” NCT00777257 ↗ |
| Known as | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04490018 ↗ |
| Known as | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01933776 ↗ |
| Known as | Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01187433 ↗ |
| Modality | Vaccine | “tetanus toxoid [TT] vaccine” PMID 18752430 ↗ Oct 2008 |
| Route | Subcutaneous | “patients receive tetanus toxoid and ALVAC-CEA-B7.1 vaccine subcutaneously (SC) once weekly for 3 weeks” NCT00027833 ↗ |